Advanced search
Publication Cover
Future Science OA Volume 4, 2018 - Issue 9
Submit an article Journal homepage
4,197
Views
33
CrossRef citations to date
0
Altmetric
Review

Recent Advances in the Discovery of Small-Molecule Inhibitors of HIV-1 Integrase

Eungi Choi1 Department of Biopharmaceutical Sciences, Keck Graduate Institute School of Pharmacy, 535, Watson Dr, Claremont, CA91711, USA
,
Jayapal Reddy Mallareddy1 Department of Biopharmaceutical Sciences, Keck Graduate Institute School of Pharmacy, 535, Watson Dr, Claremont, CA91711, USA
,
Dai Lu2 Department of Pharmaceutical Sciences, Texas A&M University School of Pharmacy, 1010 W. Avenue B, Kingsville, TX78363, USA
&
Srikanth Kolluru1 Department of Biopharmaceutical Sciences, Keck Graduate Institute School of Pharmacy, 535, Watson Dr, Claremont, CA91711, USACorrespondence[email protected]
Article: FSO338 | Received 01 Jun 2018, Accepted 25 Jul 2018, Published online: 06 Sep 2018

References

  • Unaids. Global Aids Update 2017. (2017). Unaids. Aidsinfo Website. http://aidsinfo.unaids.org/.
  • Prevention CFDCaMSNHPaCOBUHSDUSaDA. (2015). HIV Surveillance Supplemental Report 2015, 22. www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-22-2.pdf.
  • Meadows DC, Gervay-Hague J. Current developments in HIV chemotherapy. Chem. Med. Chem. 1(1), 16–29 (2006).
  • Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment. Curr. Opin. HIV AIDS 10(4), 246–252 (2015).
  • Passaes CP, Saez-Cirion A. HIV cure research: advances and prospects. Virology 454–455, 340–352 (2014).
  • Burgos J, Ribera E, Falco V. Antiretroviral therapy in advanced HIV disease: which is the best regimen? AIDS Rev. 20(1), 3–13 (2018).
  • De Clercq E. New approaches toward anti-HIV chemotherapy. J. Med. Chem. 48(5), 1297–1313 (2005).
  • Gulick RM. Investigational antiretroviral drugs: what is coming down the pipeline. Top. Antivir. Med. 25(4), 127–132 (2018).
  • Summa V, Petrocchi A, Bonelli F et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51(18), 5843–5855 (2008).
  • Shimura K, Kodama E, Sakagami Y et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82(2), 764–774 (2008).
  • Demarest J, Underwood M, St Clair M, Dorey D, Brown D, Zolopa A. Short communication: dolutegravir-based regimens are active in integrase strand transfer inhibitor-naive patients with nucleoside reverse transcriptase inhibitor resistance. AIDS Res. Hum. Retroviruses 34(4), 343–346 (2018).
  • Unger NR, Worley MV, Kisgen JJ, Sherman EM, Childs-Kean LM. Elvitegravir for the treatment of HIV. Expert Opin. Pharmacother. 17(17), 2359–2370 (2016).
  • Rathbun RC, Lockhart SM, Miller MM, Liedtke MD. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection. Ann. Pharmacother. 48(3), 395–403 (2014).
  • Métifiot M, Marchand C, Pommier Y. HlV integrase inhibitors: 20-year landmark and challenges. Anti-Viral Agents 67, 75 (2013).
  • Engelman AN, Singh PK. Cellular and molecular mechanisms of HIV-1 integration targeting. Cell. Mol. Life Sci. doi:10.1007/s00018-018-2772-5 (2018) ( Epub ahead of print).
  • Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67(6), 1211–1221 (1991).
  • Brown PO, Bowerman B, Varmus HE, Bishop JM. Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein. Proc. Natl Acad. Sci. USA 86(8), 2525–2529 (1989).
  • Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4(3), 236–248 (2005).
  • Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 52, 351–369 (1999).
  • Engelman A, Bushman FD, Craigie R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J. 12(8), 3269 (1993).
  • Zeinalipour-Loizidou E, Nicolaou C, Nicolaides A, Kostrikis LG. HIV-1 integrase: from biology to chemotherapeutics. Curr. HIV Res. 5(4), 365–388 (2007).
  • Cai M, Zheng R, Caffrey M, Craigie R, Clore GM, Gronenborn AM. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 4(7), 567–577 (1997).
  • Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266(5193), 1981–1986 (1994).
  • Lodi PJ, Ernst JA, Kuszewski J et al. Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 34(31), 9826–9833 (1995).
  • Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464(7286), 232–236 (2010).
  • Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 4(9), 965–977 (2004).
  • Vandegraaff N, Engelman A. Molecular mechanisms of HIV integration and therapeutic intervention. Expert Rev. Mol. Med. 9(6), 1–19 (2007).
  • Turlure F, Devroe E, Silver PA, Engelman A. Human cell proteins and human immunodeficiency virus DNA integration. Front. Biosci. 9, 3187–3208 (2004).
  • Li Y, Xuan S, Feng Y, Yan A. Targeting HIV-1 integrase with strand transfer inhibitors. Drug Discov. Today 20(4), 435–449 (2015).
  • Blanco JL, Whitlock G, Milinkovic A, Moyle G. HIV integrase inhibitors: a new era in the treatment of HIV. Expert Opin. Pharmacother. 16(9), 1313–1324 (2015).
  • Semenova EA, Marchand C, Pommier Y. HIV-I integrase inhibitors: update and perspectives. Adv. Pharmacol. 56, 199 (2008).
  • Wong E, Trustman N, Yalong A. HIV pharmacotherapy: a review of integrase inhibitors. JAAPA 29(2), 36–40 (2016).
  • Bonnenfant S, Thomas CM, Vita C et al. Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J. Virol. 78(11), 5728–5736 (2004).
  • Marchand C, Krajewski K, Lee H-F et al. Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites. Nucleic Acids Res. 34(18), 5157–5165 (2006).
  • Metifiot M, Johnson BC, Kiselev E et al. Selectivity for strand-transfer over 3′-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site. Nucleic Acids Res. 44(14), 6896–6906 (2016).
  • Di Santo R, Costi R, Roux A et al. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. J. Med. Chem. 49(6), 1939–1945 (2006).
  • Costi R, Di Santo R, Artico M et al. 6-aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays. Bioorg. Med. Chem. Lett. 14(7), 1745–1749 (2004).
  • Goldgur Y, Craigie R, Cohen GH et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl Acad. Sci. USA 96(23), 13040–13043 (1999).
  • Fujishita TY T, Sato A, (Shionogi & Co., Ltd.). Preparation of aromatic heterocycle compounds having HIV integrase inhibiting activities. PCT Int. Appl. WO-00039086, 554 (2000).
  • Hazuda DJ. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287(5453), 646–650 (2000).
  • Young SD, Egbertson M, Payne LS et al. Preparation of aromatic and heteroaromatic 4-aryl-2,4-dioxobutyric acid derivatives useful as HIV integrase inhibitors. PCT Int. Appl. WO-9962520, 319 (1999).
  • Marchand C, Zhang X, Pais GC et al. Structural determinants for HIV-integrase inhibition by β-diketo acids. J. Bio. Chem. 277(15), 12596–12603 (2002).
  • Zhuang L, Wai JS, Embrey MW et al. Design and synthesis of 8-hydroxy-[1,6] naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 46(4), 453–456 (2003).
  • Hazuda DJ, Anthony NJ, Gomez RP et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl Acad. Sci. USA 101(31), 11233–11238 (2004).
  • Nair V, Okello M. Integrase inhibitor prodrugs: approaches to enhancing the anti-HIV activity of beta-diketo acids. Molecules 20(7), 12623–12651 (2015).
  • Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Investig. Drugs 4(2), 206–209 (2003).
  • Rosemond M, St John-Williams L, Yamaguchi T, Fujishita T, Walsh JS. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem. Biol. Interact. 147(2), 129–139 (2004).
  • Garvey EP, Johns BA, Gartland MJ et al. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob. Agents Chemother. 52(3), 901–908 (2008).
  • Korolev S, Agapkina YY, Gottikh M. Clinical use of inhibitors of HIV-1 integration: problems and prospects. Acta Naturae 3(3), 12 (2011).
  • Long YQ, Jiang XH, Dayam R et al. Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase. J. Med. Chem. 47(10), 2561–2573 (2004).
  • Walker MA, Johnson T, Ma Z et al. Triketoacid inhibitors of HIV-integrase: a new chemotype useful for probing the integrase pharmacophore. Bioorg. Med. Chem. Lett. 16(11), 2920–2924 (2006).
  • Grobler JA, Stillmock K, Hu B et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA 99(10), 6661–6666 (2002).
  • Marchand C, Johnson AA, Karki RG et al. Metal-dependent inhibition of HIV-1 integrase by β-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol. 64(3), 600–609 (2003).
  • Pais GC, Zhang X, Marchand C et al. Structure activity of 3-Aryl-1, 3-diketo-containing compounds as HIV-1 integrase inhibitors 1. J. Med. Chem. 45(15), 3184–3194 (2002).
  • Liedtke MD, Tomlin CR, Lockhart SM, Miller MM, Rathbun RC. Long-term efficacy and safety of raltegravir in the management of HIV infection. Infect. Drug Resist. 7, 73–84 (2014).
  • Jaeckle M, Khaykin P, Haberl A et al. Efficacy of raltegravir-containing regimens in antiretroviral-naive and -experienced individuals in routine clinical practice. Int. J. STD AIDS 27(13), 1170–1179 (2016).
  • Deeks ED. Raltegravir once-daily tablet: a review in HIV-1 infection. Drugs 77(16), 1789–1795 (2017).
  • De Miguel R, Montejano R, Stella-Ascariz N, Arribas JR. A safety evaluation of raltegravir for the treatment of HIV. Expert Opin. Drug Saf. 17(2), 217–223 (2018).
  • Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359(4), 339–354 (2008).
  • Markowitz M, Nguyen B-Y, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46(2), 125–133 (2007).
  • Jegede O, Babu J, Di Santo R, Mccoll DJ, Weber J, Quinones-Mateu M. HIV type 1 integrase inhibitors: from basic research to clinical implications. AIDS Rev. 10(3), 172–189 (2008).
  • Corona A, Di Leva FS, Rigogliuso G et al. New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H. Antiviral Res. 134, 236–243 (2016).
  • Corona A, Di Leva FS, Thierry S et al. Identification of highly conserved residues involved in inhibition of HIV-1 RNase H function by Diketo acid derivatives. Antimicrob. Agents Chemother. 58(10), 6101–6110 (2014).
  • Imaz A, Podzamczer D. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. Expert Rev. Anti. Infect. Ther. 15(3), 195–209 (2017).
  • Angione SA, Cherian SM, Ozdener AE. A review of the efficacy and safety of Genvoya(R) (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) in the management of HIV-1 infection. J. Pharm. Pract. 31(2), 216–221 (2018).
  • Sato M, Motomura T, Aramaki H et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 49(5), 1506–1508 (2006).
  • Sato M, Kawakami H, Motomura T et al. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. J. Med. Chem. 52(15), 4869–4882 (2009).
  • Naccarato MJ, Yoong DM, Fong IW, Gough KA, Ostrowski MA, Tan DHS. Combination therapy with tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat plus darunavir once daily in antiretroviral-naive and treatment-experienced patients: a retrospective review. J. Int. Assoc. Provid. AIDS Care. 17, 2325957417752260 (2018).
  • Abram ME, Hluhanich RM, Goodman DD et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob. Agents Chemother. 57(6), 2654–2663 (2013).
  • Anstett K, Brenner B, Mesplede T, Wainberg MA. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology 14(1), 36 (2017).
  • Johns BA, Kawasuji T, Weatherhead JG et al. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J. Med. Chem. 56(14), 5901–5916 (2013).
  • Kobayashi M, Yoshinaga T, Seki T et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55(2), 813–821 (2011).
  • Dow DE, Bartlett JA. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect. Dis. Ther. 3(2), 83–102 (2014).
  • Hare S, Smith SJ, Metifiot M et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol. Pharmacol. 80(4), 565–572 (2011).
  • Di Santo R. Inhibiting the HIV integration process: past, present, and the future. J. Med. Chem. 57(3), 539–566 (2014).
  • Jones GS, Yu F, Zeynalzadegan A et al. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob. Agents Chemother. 53(3), 1194–1203 (2009).
  • Ramkumar K, Serrao E, Odde S, Neamati N. HIV-1 integrase inhibitors: 2007–2008 update. Med. Res. Rev. 30(6), 890–954 (2010).
  • Goethals O, Van Ginderen M, Vos A et al. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Res. 91(2), 167–176 (2011).
  • Bar-Magen T, Sloan RD, Donahue DA et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 84(18), 9210–9216 (2010).
  • Pandey KK, Bera S, Vora AC, Grandgenett DP. Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors. Biochemistry 49(38), 8376–8387 (2010).
  • Marsden MD, Avancena P, Kitchen CM, Hubbard T, Zack JA. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob. Agents Chemother. 55(8), 3696–3702 (2011).
  • Zhang D, Debnath B, Yu S et al. Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase. Bioorg. Med. Chem. doi:10.1016/j.bmc.2014.07.036 (2014) ( Epub ahead of print).
  • Karmon SL, Markowitz M. Next-generation integrase inhibitors: where to after raltegravir? Drugs 73(3), 213–228 (2013).
  • Johns BA, Kawasuji T, Weatherhead JG et al. Naphthyridinone (NTD) integrase inhibitors: N1 protio and methyl combination substituent effects with C3 amide groups. Bioorg. Med. Chem. Lett. 23(2), 422–425 (2013).
  • Ford SL, Gould E, Chen S et al. Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744. Antimicrob. Agents Chemother. 57(1), 277–280 (2013).
  • Mcpherson TD, Sobieszczyk ME, Markowitz M. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1. Expert Opin. Investig. Drugs 27(4), 413–420 (2018).
  • Spreen W, Min S, Ford SL et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin. Trials 14(5), 192–203 (2013).
  • Abraham BK, Gulick R. Next-generation oral preexposure prophylaxis: beyond tenofovir. Curr. Opin. HIV AIDS 7(6), 600–606 (2012).
  • Saag MS. New and investigational antiretroviral drugs for HIV infection: mechanisms of action and early research findings. Top. Antivir. Med. 20(5), 162–167 (2012).
  • Tsiang M, Jones GS, Goldsmith J et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob. Agents Chemother. 60(12), 7086–7097 (2016).
  • Gallant JE, Thompson M, Dejesus E et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J. Acquir. Immune Defic. Syndr. 75(1), 61–66 (2017).
  • Markham A. Bictegravir: first global approval. Drugs 78(5), 601–606 (2018).
  • Zhao XZ, Smith SJ, Metifiot M et al. Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants. J. Med. Chem. 57(4), 1573–1582 (2014).
  • Burlein C, Wang C, Xu M et al. Discovery of a distinct chemical and mechanistic class of allosteric HIV-1 integrase inhibitors with antiretroviral activity. ACS Chem. Biol. 12(11), 2858–2865 (2017).
  • Christ F, Shaw S, Demeulemeester J et al. Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob. Agents Chemother. 56(8), 4365–4374 (2012).
  • Fenwick C, Amad M, Bailey MD et al. Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor. Antimicrob. Agents Chemother. 58(6), 3233–3244 (2014).
  • Bonnard D, Le Rouzic E, Eiler S et al. Structure-function analyses unravel distinct effects of allosteric inhibitors of HIV-1 integrase on viral maturation and integration. J. Biol. Chem. 293(16), 6172–6186 (2018).
  • Peat TS, Dolezal O, Newman J, Mobley D, Deadman JJ. Interrogating HIV integrase for compounds that bind–a SAMPL challenge. J. Comput. Aided Mol. Des. 28(4), 347–362 (2014).
  • Gu WG, Ip DT, Liu SJ et al. 1,4-Bis(5-(naphthalen-1-yl)thiophen-2-yl)naphthalene, a small molecule, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular Lens epithelium-derived growth factor. Chem. Biol. Interact. 213, 21–27 (2014).
  • Blokken J, De Rijck J, Christ F, Debyser Z. Protein–protein and protein–chromatin interactions of LEDGF/p75 as novel drug targets. Drug Discov. Today. Technol. 24, 25–31 (2017).
  • Christ F, Voet A, Marchand A et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol. 6(6), 442–448 (2010).
  • Desimmie BA, Schrijvers R, Demeulemeester J et al. LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology 10, 57 (2013).
  • Christ F, Debyser Z. The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology 435(1), 102–109 (2013).
  • Christ F, Debyser Z. HIV-1 integrase inhibition: looking at cofactor interactions. Future Med. Chem. 7(18), 2407–2410 (2015).
  • Xue W, Liu H, Yao X. Molecular modeling study on the allosteric inhibition mechanism of HIV-1 integrase by LEDGF/p75 binding site inhibitors. PLoS ONE 9(3), e90799 (2014).
  • De Luca L, Ferro S, Morreale F, De Grazia S, Chimirri A. Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75. Chem. Med. Chem. 6(7), 1184–1191 (2011).
  • Du L, Zhao Y, Chen J et al. D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem. Biophys. Res. Commun. 375(1), 139–144 (2008).
  • Kang D, Song Y, Chen W, Zhan P, Liu X. ‘Old Dogs with New Tricks’: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets. Mol. Biosyst. 10(8), 1998–2022 (2014).
  • Le Rouzic E, Bonnard D, Chasset S et al. Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. Retrovirology 10, 144 (2013).
  • Sharma A, Slaughter A, Jena N et al. A new class of multimerization selective inhibitors of HIV-1 integrase. PLoS Pathog. 10(5), e1004171 (2014).
  • Kessl JJ, Jena N, Koh Y et al. Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J. Biol. Chem. 287(20), 16801–16811 (2012).
  • Feng L, Sharma A, Slaughter A et al. The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors. J. Biol. Chem. 288(22), 15813–15820 (2013).
  • Fan X, Zhang FH, Al-Safi RI et al. Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups. Bioorg. Med. Chem. 19(16), 4935–4952 (2011).
  • Zhang FH, Debnath B, Xu ZL et al. Discovery of novel 3-hydroxypicolinamides as selective inhibitors of HIV-1 integrase-LEDGF/p75 interaction. Eur. J. Med. Chem. 125, 1051–1063 (2017).
  • George A, Gopi Krishna Reddy A, Satyanarayana G, Raghavendra NK. 1,2,3,4-Tetrahydroisoquinolines as inhibitors of HIV-1 integrase and human LEDGF/p75 interaction. Chem. Biol. Drug Des. doi:10.1111/cbdd.13175 (2018) ( Epub ahead of print).
  • Panwar U, Singh SK. Structure-based virtual screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and human lens epithelium-derived growth factor (LEDGF/p75). J. Biomol. Struct. Dyn. doi: 10.1080/07391102.2017.13844001-19 (2017) ( Epub ahead of print).
  • Cuzzucoli Crucitti G, Pescatori L, Messore A et al. Discovery of N-aryl-naphthylamines as in vitro inhibitors of the interaction between HIV integrase and the cofactor LEDGF/p75. Eur. J. Med. Chem. 101, 288–294 (2015).
  • Han Y, Mesplede T, Wainberg MA. Investigational HIV integrase inhibitors in Phase I and Phase II clinical trials. Expert Opin. Investig. Drugs 26(11), 1207–1213 (2017).
  • Fader LD, Malenfant E, Parisien M et al. Discovery of BI 224436, a noncatalytic site integrase inhibitor (NCINI) of HIV-1. ACS Med. Chem. Lett. 5(4), 422–427 (2014).
  • Engelman A, Kessl JJ, Kvaratskhelia M. Allosteric inhibition of HIV-1 integrase activity. Curr. Opin. Chem. Biol. 17(3), 339–345 (2013).
  • Krishnan L, Engelman A. Retroviral integrase proteins and HIV-1 DNA integration. J. Biol. Chem. 287(49), 40858–40866 (2012).
  • Taltynov O, Desimmie BA, Demeulemeester J, Christ F, Debyser Z. Cellular cofactors of lentiviral integrase: from target validation to drug discovery. Mol. Biol. Int. 2012, 863405 (2012).
  • Amadori C, Van Der Velden YU, Bonnard D et al. The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. Retrovirology 14(1), 50 (2017).
  • Wang Y, Lin HQ, Wang P et al. Discovery of a novel HIV-1 integrase/p75 interacting inhibitor by docking screening, biochemical assay, and in vitro studies. J. Chem. Inf. Model. 57(9), 2336–2343 (2017).
  • Barreca ML, Ferro S, Rao A et al. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem. 48(22), 7084–7088 (2005).
  • De Luca L, Ferro S, Gitto R et al. Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg. Med. Chem. 18(21), 7515–7521 (2010).
  • Hoyte AC, Jamin AV, Koneru PC et al. Resistance to pyridine-based inhibitor KF116 reveals an unexpected role of integrase in HIV-1 Gag-Pol polyprotein proteolytic processing. J. Biol. Chem. 292(48), 19814–19825 (2017).
  • Jampilek J, Musiol R, Finster J et al. Investigating biological activity spectrum for novel styrylquinazoline analogues. Molecules 14(10), 4246–4265 (2009).
  • Serrao E, Debnath B, Otake H et al. Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction. J. Med. Chem. 56(6), 2311–2322 (2013).
  • Li BW, Zhang FH, Serrao E et al. Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75. Bioorg. Med. Chem. 22(12), 3146–3158 (2014).
  • Harrison AT, Kriel FH, Papathanasopoulos MA, Mosebi S, Abrahams S, Hewer R. The evaluation of statins as potential inhibitors of the LEDGF/p75-HIV-1 integrase interaction. Chem. Biol. Drug Des. doi:10.1111/cbdd.12384 (2014) ( Epub ahead of print).
  • Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L et al. Dual antiretroviral therapy for HIV infection. Expert Opin. Drug Saf. 16(8), 923–932 (2017).
  • Gu SX, Xue P, Ju XL, Zhu YY. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase. Bioorg. Med. Chem. 24(21), 5007–5016 (2016).
  • Billamboz M, Bailly F, Barreca ML et al. Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. J. Med. Chem. 51(24), 7717–7730 (2008).
  • Tang J, Vernekar SKV, Chen YL et al. Synthesis, biological evaluation and molecular modeling of 2-hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase. Eur. J. Med. Chem. 133, 85–96 (2017).
  • Suchaud V, Bailly F, Lion C et al. Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors. J. Med. Chem. 57(11), 4640–4660 (2014).
  • Billamboz M, Suchaud V, Bailly F et al. 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: influence of the alkylcarboxamide substitution of position 4. Eur. J. Med. Chem. 117, 256–268 (2016).
  • Costi R, Metifiot M, Chung S et al. Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase. J. Med. Chem. 57(8), 3223–3234 (2014).
  • Pescatori L, Metifiot M, Chung S et al. N-substituted quinolinonyl diketo acid derivatives as HIV integrase strand transfer inhibitors and their activity against RNase H function of reverse transcriptase. J. Med. Chem. 58(11), 4610–4623 (2015).
  • Costi R, Metifiot M, Esposito F et al. 6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach. J. Med. Chem. 56(21), 8588–8598 (2013).
  • Cuzzucoli Crucitti G, Metifiot M, Pescatori L et al. Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain. J. Med. Chem. 58(4), 1915–1928 (2015).
  • Rogolino D, Carcelli M, Compari C et al. Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process. Eur. J. Med. Chem. 78, 425–430 (2014).
  • De Luca L, Barreca ML, Ferro S et al. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. Chem. Med. Chem. 4(8), 1311–1316 (2009).
  • Ferro S, De Luca L, Lo Surdo G et al. A new potential approach to block HIV-1 replication via protein-protein interaction and strand-transfer inhibition. Bioorg. Med. Chem. 22(7), 2269–2279 (2014).
  • Tsiang M, Jones GS, Niedziela-Majka A et al. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J. Biol. Chem. 287(25), 21189–21203 (2012).
  • Gupta K, Turkki V, Sherrill-Mix S et al. Structural basis for inhibitor-induced aggregation of HIV integrase. PLoS Biol. 14(12), e1002584 (2016).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.